The latest price target for Mersana Therapeutics (NASDAQ:MRSN) was reported by Citigroup on August 27, 2024. The analyst firm set a price target for $5.00 expecting MRSN to rise to within 12 months (a possible 135.85% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Mersana Therapeutics (NASDAQ:MRSN) was provided by Citigroup, and Mersana Therapeutics maintained their buy rating.

The last upgrade for Mersana Therapeutics Inc happened on March 19, 2024 when JP Morgan raised their price target to $5. JP Morgan previously had an underweight for Mersana Therapeutics Inc.

The last downgrade for Mersana Therapeutics Inc happened on July 28, 2023 when Citigroup changed their price target from $10 to $1 for Mersana Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mersana Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mersana Therapeutics was filed on August 27, 2024 so you should expect the next rating to be made available sometime around August 27, 2025.

While ratings are subjective and will change, the latest Mersana Therapeutics (MRSN) rating was a maintained with a price target of $6.00 to $5.00. The current price Mersana Therapeutics (MRSN) is trading at is $2.12, which is out of the analyst’s predicted range.